Clinical evaluation of DQ-2556 on bacterial infections in the field of internal medicine

Kaoru Shimada, Hajime Goto, Shinichi Oka, Yasuyuki Sano, Yasufumi Miyamoto, Takashi Inamatsu, Hiroyuki Kobayashi, Hiroaki Takeda, Toru Sakayori, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Masashi Tamura, Kazuki Konishi, Masakichi Motomiya, Akira Watanabe, Toshio Nakamura, Hideo TogashiKotaro Oizumi, Kohya Shiba, Masaki Yoshida, Osamu Sakai, Jingoro Shimada, Hiroichi Tanimoto, Kazuo Ohara, Koichiro Nakata, Yoshitaka Nakamori, Kihachiro Shimizu, Kyouichi Totsuka, Takao Okubo, Hirotada Ikeda, Shigeki Odagiri, Fumio Matsumoto, Takeo Imai, Nobuki Aoki, Masaaki Arakawa, Kouichi Wada, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Hidekazu Hanaki, Masahito Kato, Yoshimasa Kondo, Ikuji Usami, Hideaki Kuroki, Toshiyuki Yamamoto, Kanzo Suzuki, Satoru Adachi, Toru Matsuura, Fumio Miki, Takao Sasaki, Yuji Sugimoto, Rinzo Soejima, Masaru Sumi, Yoshihito Niki, Jiro Hino, Michio Yamakido, Kenji Hasegawa, Kohei Hara, Shigeru Kohno, Hironobu Koga, Yasumasa Doutsu, Takashige Miyazaki, Koichi Watanabe, Keizo Matsumoto, Naoto Rikitomi, Mikio Taguchi, Masaru Nasu, Yoichiro Goto, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Jun Inatome, Keizo Yamaguchi, Nobuya Ogawa, Mitsuo Kaku, Kazuyuki Sugawara, Koichi Deguchi

Research output: Contribution to journalArticle

Abstract

The clinical usefulness of DQ-2556, a new parenteral cephem antibiotic, in the treatment of bacterial infections in the field of internal medicine and its optimal dosage in the treatment of pneumonia were investigated. 1. Open clinical studies DQ-2556 was administered mainly at doses of 0.5 g b. i. d. and 1.0 g b. i. d. The clinical efficacy rates for lower respiratory tract infections were 76.5% (26/34) for pneumonia, 7/9 for secondary infections of chronic respiratory diseases, and 6/7 for bronchiectasis with infections, or 78.0% (46/ 59) overall. Efficacy rates classified by daily dosages were 73.7% (14/19) at 0.5 g b.i.d. and 83.3 % (30/36) at l.Og b.i.d. The eradication rates of causative bacteria were 86, 4% (19/22) for monomicrobial infections and 4/6 for polymicrobial infections, thus 82.1% (23/28) overall. The eradication rate for Staphylococcus aureus was 5/9, and five strains of Streptococcus pneumoniae, eight strains of Haemophilus influenzae and four strains of Moraxella catarrhalis were all eradicated. Three evaluable patients with urinary tract infections all showed bacterial eradication and good or excellent clinical efficacy. Side effects were observed in three patients (incidence 3.9%) with one each, showing eruption, angina pectoris and diarrhea, all three were treated at dosages of 1.0 g per time. Abnormal changes in laboratory test results, the most of which were abnormalities in liver function, were seen in 8.3% (2/24) at daily dosages of 0.5 g b.i.d. and in 23.9% (11/46) at daily dosages of 1.0g b.i.d. 2. Dose-finding study Clinical efficacies for pneumonia were compared among two groups treated with DQ-2556 at daily dosages of 0.5 g b. i. d. (DQ-1.0 group) and of 1.0 g b. i. d. (DQ-2.0 group) and the control group with treated with ceftazidime (CAZ) at daily dosages of l.Og b.i.d. (CAZ group). The overall clinical efficacy rates in the DQ-1.0 group, the DQ-2.0 group and the CAZ group were 94.4% (17/ 18), 82.4% (14/17) and 94.4% (17/18), respectively, without any significant differences among the three groups. The overall eradication rates of causative bacteqa in the DQ-1.0 group, the DQ-2.0 group and the CAZ group were 8/8, 8/8 and 5/6, respectively, without any significant differences among the three groups. The only side effect, eruption with fever, was observed in a patient in the DQ-2.0 group. Abnormal changes in laboratory test results were seen in 13.6% (3/22) of the DQ-1.0 group, 30.0% (6/20) of the DQ-2.0 group and 28.6% (6/21) of the CAZ group, the incidence was lower in the DQ-1.0 group than in the other two groups, but no significant differences were not noted among the three groups. Most of the abnormalities were seen in items of liver function. There were no significant differences among the three groups in the overall clinical utility rates. These results suggest that DQ-2556 is a useful antibiotic for treatment of lower respiratory tract infections, including pneumonia, and a dosage of 0.5g b.i.d. is sufficient to exert good clinical effects on pneumonia. It is also considered that DQ-2556 may show almost the same degree of safety as CAZ, but an increased number of evaluable patients will required to clarify this.

Original languageEnglish
Pages (from-to)886-910
Number of pages25
JournalChemotherapy
Volume41
Issue number8
DOIs
Publication statusPublished - 1993

Keywords

  • DQ-2556

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Clinical evaluation of DQ-2556 on bacterial infections in the field of internal medicine'. Together they form a unique fingerprint.

  • Cite this

    Shimada, K., Goto, H., Oka, S., Sano, Y., Miyamoto, Y., Inamatsu, T., Kobayashi, H., Takeda, H., Sakayori, T., Saito, A., Nakayama, I., Tomizawa, M., Hiraga, Y., Ohmichi, M., Tamura, M., Konishi, K., Motomiya, M., Watanabe, A., Nakamura, T., ... Deguchi, K. (1993). Clinical evaluation of DQ-2556 on bacterial infections in the field of internal medicine. Chemotherapy, 41(8), 886-910. https://doi.org/10.11250/chemotherapy1953.41.886